Rhabdomyolysis - a Study of Patients and Laboratory Values to Guide Treatment
RhabdoGuide
1 other identifier
observational
310
1 country
1
Brief Summary
Rhabdomyolysis is a potentially life-threatening syndrome characterized by breakdown of skeletal muscle, and leakage of intracellular substances such as myoglobin and creatine kinase (CK) into the circulation. The aetiological spectrum of rhabdomyolysis is extensive, and the clinical spectrum varies from a transient subclinical increase in CK activity to acute kidney injury (AKI) as a serious complication. There are no large prospective studies and only a few retrospective studies on rhabdomyolysis.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Aug 2019
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
August 4, 2019
CompletedFirst Submitted
Initial submission to the registry
September 20, 2019
CompletedFirst Posted
Study publicly available on registry
October 8, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 22, 2023
CompletedStudy Completion
Last participant's last visit for all outcomes
December 22, 2023
CompletedMarch 7, 2025
March 1, 2025
4.4 years
September 20, 2019
March 6, 2025
Conditions
Outcome Measures
Primary Outcomes (2)
Development of Acute Kidney Injury (AKI)
AKI will be defined according to KDIGO 2012 guidelines
Change of creatinine from baseline (KDIGO 2012 guidelines) through hospitalization (average 1 week)
Kidney function after three months and development of Chronic Kidney Disease (CKD)
Change in kreatinine and/or eGFR. CKD classifications followed KDIGO stages I-V
3 months
Secondary Outcomes (4)
Other complications
During hospitalization (average 1 week)
Risk stratification based on Myoglobin/Creatine kinase ratio
Change of creatinine from baseline (KDIGO 2012 guidelines) through hospitalization (average 1 week)
Association between rhabdomyolysis, elevated cardiac enzymes and the effect on myocardium.
Through hospitalization (average 1 week)
Risk stratification based on Myoglobin and Creatine kinase
Through hospitalization (average 1 week)
Interventions
No intervention
Eligibility Criteria
This will be a prospective observational cohort study on patients with rhabdomyolysis admitted to emergency departments. Both medical and surgical/trauma departments will be included.
You may not qualify if:
- Sub-study on rhabdomyolysis and cardiac enzymes:
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Oslo University Hospitallead
- Lovisenberg Diakonale Hospitalcollaborator
- Diakonhjemmet Hospitalcollaborator
- University Hospital, Akershuscollaborator
Study Sites (1)
Oslo University Hospital, Ullevaal
Oslo, 0450, Norway
Related Publications (1)
Vangstad M, Gulsvik AK, Kro Birkeland JA, Ervik RL, Brekke FB, Akkouh OA, Jacobsen D, Bjornaas MA. Myoglobin-to-creatine kinase ratio enhances prediction of acute kidney injury in rhabdomyolysis. Emerg Med J. 2026 Jan 28:emermed-2025-215470. doi: 10.1136/emermed-2025-215470. Online ahead of print.
PMID: 41605622DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Vangstad
University of Oslo
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Project manager
Study Record Dates
First Submitted
September 20, 2019
First Posted
October 8, 2019
Study Start
August 4, 2019
Primary Completion
December 22, 2023
Study Completion
December 22, 2023
Last Updated
March 7, 2025
Record last verified: 2025-03
Data Sharing
- IPD Sharing
- Will not share